Arizona Blood & Cancer Specialists, OneOncology & TMC Healthcare Open Two Radiation Oncology Centers
Arizona Blood and Cancer Specialists (ABCS), OneOncology, and TMC HealthCare (TMC) today announced that through their joint venture, they have […]
Memorial Sloan Kettering Study Takes on Esophagus Cancer with Combo of Chemo, PD-1 Blocker & Tyrosine Kinase Inhibitor
Memorial Sloan Kettering Cancer Center announced the launch of a Phase 2 study led by Yelena Y. Janjigian and Smita Joshi, which […]
Parker Institute for Cancer Immunotherapy Awards $3m to Early Career Investigators in Ongoing Fight Against Cancer Thanks to Tech Riches
The Parker Institute for Cancer Immunotherapy (PICI) recently announced its 2021 class of early career researcher award recipients, a group […]
BlossomHill Therapeutics Completes $71M Series A Round to Progress Pipeline of Small Molecule Drugs for Oncology, Autoimmune Disorders
BlossomHill Therapeutics raised $71 million in a Series A financing round, led by Cormorant Asset Management LLC and joined by Hercules BioVentures […]
University of Kansas Cancer Center Introduces the Next Level App Supporting the Growing Clinical Research as a Care Option Advance
The University of Kansas Cancer Center has developed a new mobile app to match anyone looking for specific cancer trials with […]
UNSW & Garvan Institute Take Precision Medicine Revolution to War Against Pancreatic Cancer in Australia
Thanks to an $3.75 million grant injection from the Cancer Institute, NSW Translational Program, researchers and clinicians from UNSW and […]
$250m Philanthropic Capital Infusion Launches Break Through Cancer Targeting Cures for Most Intractable Cancers
One of the largest gifts, even in support of cancer research, $250 million thanks to Mr. and Mrs. William H. […]
UCSF Develops Research as a Care Option Decision, Supporting Tool for Prostate Cancer Patients
One of the biggest challenges facing clinical trial sponsors and investigational sites centers on the efficient identification, recruitment and ongoing […]
AstraZeneca’s Phase 3 KESTREL Trial of Imfinzi Fails to Meet the Primary Endpoint in Patients with Head and Neck Cancer
AstraZeneca reported that its Phase 3 KESTREL trial of Imfinzi (durvalumab) failed to meet the primary endpoint of improving overall […]
Regeneron’s Libtayo Approved by the FDA as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
The U.S. Food and Drug Administration granted approval of a drug that is the first immunotherapy treatment indicated for patients […]
